CeriBell Inc

CBLL

Market cap $664M

SUNNYVALE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 46th Annual Growth Stock Conference in Chicago. The presentation will take place on Wednesday, June 3, 2026, at 9:20 a.m. Pacific Daylight Time / 11:20 a.m. Central Daylight Time.

CeriBell NASDAQ: CBLL executives said the company's first-quarter results reflected continued momentum in both new account additions and increased usage among existing hospital customers, while outlining early progress in new clinical areas including neonatal seizure monitoring and delirium.

CeriBell, Inc. (CBLL) Presents at Bank of America Global Healthcare Conference 2026 Transcript

CeriBell, Inc. (CBLL) Q1 2026 Earnings Call Transcript

CeriBell NASDAQ: CBLL reported first-quarter revenue growth of 29% and raised its full-year outlook, as management cited higher usage of its seizure monitoring system and the company's strongest quarter of net new hospital additions since becoming public.

CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.36 per share a year ago.

SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the first quarter ended March 31, 2026.

SUNNYVALE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D.

SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the first quarter of 2026 after the close of trading on Monday, May 11, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on May 11, 2026.

The Fund rebounded and outperformed the Russell 2000 ® Growth Index in the fourth quarter. Boot Barn's revenues and earnings handily exceeded estimates, with greater transaction volumes and new store openings. Abivax reported strong clinical trial results for its obefazimod treatment to address ulcerative colitis in a longer lasting manner.